


Jardiance[®]
(empagliflozin)


Synjardy[®]
(empagliflozin/
metformin HCl)

DOSING GUIDE

JARDIANCE^{®1}

Monotherapy: JARDIANCE[®] (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance.

Add-on combination: JARDIANCE[®] is indicated in adult patients with T2DM to improve glycemic control in combination with metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin), when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control.

Add-on combination in patients with established cardiovascular disease: JARDIANCE[®] is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in adult patients with T2DM and established cardiovascular disease.

Important limitation of use: Use of JARDIANCE[®] with insulin mix (regular or analogue mix) has not been studied. Therefore, JARDIANCE[®] should not be used with insulin mix.

SYNJARDY^{®2}

SYNJARDY[®] (empagliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on:

- metformin
- sulfonylurea in combination with metformin
- pioglitazone in combination with metformin
- insulin in combination with metformin

Or in patients already being treated and achieving glycemic control with:

- metformin and empagliflozin as separate tablets
- sulfonylurea in combination with metformin and empagliflozin as separate tablets
- pioglitazone in combination with metformin and empagliflozin as separate tablets
- insulin in combination with metformin and empagliflozin as separate tablets

JARDIANCE[®] offers convenient, once-daily oral dosing¹

JARDIANCE[®] DOSING

Recommended
starting dose

10 mg OD



Increase to

25 mg OD



In patients tolerating JARDIANCE[®]
10 mg OD and requiring additional
glycemic control

Tablets shown are not actual size.

With or without food, at any time of the day



Dosing considerations

- Assess renal function prior to initiation and regularly thereafter
- Assess volume status and, if necessary, correct volume depletion prior to initiation
- When added to insulin or an insulin secretagogue (e.g., sulfonylurea), a lower dose of the insulin or insulin secretagogue may be considered to reduce the risk of hypoglycemia
- Use with caution in patients taking diuretics, particularly loop diuretics

Considerations for special populations

Renal impairment: The glucose-lowering efficacy of JARDIANCE[®] declines with decreasing renal function. No dosage adjustment needed for T2DM patients with eGFR ≥ 30 mL/min/1.73 m². Discontinue in patients with T2DM if eGFR falls persistently < 30 mL/min/1.73 m². Not recommended

OD=once daily; eGFR=estimated glomerular filtration rate.

for use in T2DM patients with eGFR 20 to < 30 mL/min/1.73 m². Contraindicated in patients treated for T2DM with severe renal impairment (eGFR < 20 mL/min/1.73 m²), end-stage renal disease (ESRD) and patients on dialysis.

Hepatic impairment: No dosage adjustment needed for patients with mild/moderate hepatic impairment. Not recommended for use in patients with severe hepatic impairment.

Geriatrics (≥ 65 years of age): No dosage adjustment required based on age. However, renal function and risk of volume depletion should be taken into account. Therapy initiation not recommended in T2DM patients aged ≥ 85 years treated for glycemic control.

Please see Product Monograph for complete dosing and administration information.

SYNJARDY[®] contains empagliflozin and metformin in a single tablet²

AVAILABLE SYNJARDY[®] DOSES

2x daily
empagliflozin/metformin



Tablets shown are not actual size.

Patients switching from separate tablets of empagliflozin (10 mg or 25 mg total daily dose) and metformin to SYNJARDY[®] should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.

The maximum recommended daily dose is 25/2000 mg.

With meals, twice daily

The dosage should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability, while not exceeding the recommended daily dose.



Please see Product Monograph for complete dosing and administration information.



Scan the QR code with your cell phone camera for more information about dosing

JARDIANCE®

Please refer to the Product Monograph at www.JardiancePM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.

SYNJARDY®

Please refer to the Product Monograph at www.SynjardyPM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.

References: 1. JARDIANCE® Product Monograph, Boehringer Ingelheim (Canada) Ltd., October 29, 2021.
2. SYNJARDY® Product Monograph, Boehringer Ingelheim (Canada) Ltd., April 28, 2020.

Jardiance[®] 
(empagliflozin)

Synjardy[®] 
(empagliflozin/
metformin HCl)

JARDIANCE® and SYNJARDY® are registered trademarks of Boehringer Ingelheim International GmbH, used under license.
EMP-CA-101516 EMP-LI-101516

 MEMBER OF
INNOVATIVE MEDICINES CANADA

 REVIEWED BY
PAAB